Form D · Biotechnology
Rani Therapeutics, LLC
San Jose, CA · CIK 0001644130
Offering snapshot reported Nov 16, 2020 · SEC filing
- Reported sold
- $50M Offering amount: $75M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Oct 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2020 | Initial | $50,000,000 | No comparison | 2 | SEC filing |
| Sep 13, 2017 | Initial | $38,663,952 | No comparison | 12 | SEC filing |
| Jun 4, 2015 | Initial | $15,486,363 | No comparison | 10 | SEC filing |
| Jun 4, 2015 | Initial | $7,650,001 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-380622
Source: Form D, filed Nov 16, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis Ausiello | Director |
| Andrew Farquharson | Director |
| Mir Hashim | Director, Executive |
| Mir Imran | Director, Executive |
| Maulik Nanavaty | Director |
| David Pyott | Director |
| Svai Sanford | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2051 Ringwood Avenue
San Jose, CA, 95131
San Jose, CA, 95131